Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy
Patients with CKD on RRT are at high risk for severe disease and mortality in COVID-19 disease. We decided to conduct an observational prospective study to evaluate antibody response after vaccination for COVID-19 in a cohort of 210 adult patients on RRT (148 on HD; 20 on PD; and 42 kidney transplan...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/9/1395 |
| _version_ | 1797481649515003904 |
|---|---|
| author | Michela Frittoli Matthias Cassia Alessandra Barassi Paola Ciceri Andrea Galassi Ferruccio Conte Mario Gennaro Cozzolino |
| author_facet | Michela Frittoli Matthias Cassia Alessandra Barassi Paola Ciceri Andrea Galassi Ferruccio Conte Mario Gennaro Cozzolino |
| author_sort | Michela Frittoli |
| collection | DOAJ |
| description | Patients with CKD on RRT are at high risk for severe disease and mortality in COVID-19 disease. We decided to conduct an observational prospective study to evaluate antibody response after vaccination for COVID-19 in a cohort of 210 adult patients on RRT (148 on HD; 20 on PD; and 42 kidney transplant recipients). Blood samples were taken before and 4 weeks after vaccination. Antibody levels were evaluated with CLIA immunoassay testing for IgG anti-trimeric spike protein of SARS-CoV-2. A positive antibody titer was present in 89.9% of HD patients, 90% of PD patients, and 52.4% of kidney transplant recipients. Non-responders were more frequent among patients on immunosuppressive therapy. Mycophenolate use in kidney transplant patients was associated with lower antibody response. The median antibody titer was 626 (228–1480) BAU/mL; higher in younger patients and those previously exposed to the virus and lower in HD patients with neoplasms and/or on immunosuppressive therapy. Only two patients developed COVID-19 in the observation period: they both had mild disease and antibody titers lower than 1000 BAU/mL. Our data show a valid response to COVID-19 mRNA vaccination in HD and PD patients and a reduced response in kidney transplant recipients. Mycophenolate was the most relevant factor associated with low response. |
| first_indexed | 2024-03-09T22:17:37Z |
| format | Article |
| id | doaj.art-d2105b4710324efcb7fabb654b461b15 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:17:37Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d2105b4710324efcb7fabb654b461b152023-11-23T19:20:18ZengMDPI AGVaccines2076-393X2022-08-01109139510.3390/vaccines10091395Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement TherapyMichela Frittoli0Matthias Cassia1Alessandra Barassi2Paola Ciceri3Andrea Galassi4Ferruccio Conte5Mario Gennaro Cozzolino6Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyRenal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyLaboratory of Clinical Biochemistry, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20122 Milan, ItalyRenal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyRenal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyRenal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyRenal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, ItalyPatients with CKD on RRT are at high risk for severe disease and mortality in COVID-19 disease. We decided to conduct an observational prospective study to evaluate antibody response after vaccination for COVID-19 in a cohort of 210 adult patients on RRT (148 on HD; 20 on PD; and 42 kidney transplant recipients). Blood samples were taken before and 4 weeks after vaccination. Antibody levels were evaluated with CLIA immunoassay testing for IgG anti-trimeric spike protein of SARS-CoV-2. A positive antibody titer was present in 89.9% of HD patients, 90% of PD patients, and 52.4% of kidney transplant recipients. Non-responders were more frequent among patients on immunosuppressive therapy. Mycophenolate use in kidney transplant patients was associated with lower antibody response. The median antibody titer was 626 (228–1480) BAU/mL; higher in younger patients and those previously exposed to the virus and lower in HD patients with neoplasms and/or on immunosuppressive therapy. Only two patients developed COVID-19 in the observation period: they both had mild disease and antibody titers lower than 1000 BAU/mL. Our data show a valid response to COVID-19 mRNA vaccination in HD and PD patients and a reduced response in kidney transplant recipients. Mycophenolate was the most relevant factor associated with low response.https://www.mdpi.com/2076-393X/10/9/1395COVID-19vaccinehumoral responseCKDRRTsafety |
| spellingShingle | Michela Frittoli Matthias Cassia Alessandra Barassi Paola Ciceri Andrea Galassi Ferruccio Conte Mario Gennaro Cozzolino Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy Vaccines COVID-19 vaccine humoral response CKD RRT safety |
| title | Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy |
| title_full | Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy |
| title_fullStr | Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy |
| title_full_unstemmed | Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy |
| title_short | Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy |
| title_sort | efficacy and safety of covid 19 vaccine in patients on renal replacement therapy |
| topic | COVID-19 vaccine humoral response CKD RRT safety |
| url | https://www.mdpi.com/2076-393X/10/9/1395 |
| work_keys_str_mv | AT michelafrittoli efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT matthiascassia efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT alessandrabarassi efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT paolaciceri efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT andreagalassi efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT ferruccioconte efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy AT mariogennarocozzolino efficacyandsafetyofcovid19vaccineinpatientsonrenalreplacementtherapy |